Citi Pharma Ltd. (CPHL) Quarterly Report - Q2 Dec 2024
CPHL reported a profit of Rs. 1.1 per share for the quarter ending December 2024. The company did not declare any cash dividend for this period.
For the last four quarters, the cumulative net income amounted to Rs. 3.6 per share, while total cash distribution was Rs. 3.3 per share.
The latest quarter's earnings per share (EPS) showed a 9.3% increase over the average of the previous four quarters. However, the cumulative net income for the last four quarters was 13% lower compared to the prior four-quarter period. Notably, CPHL has not reported a loss in any of the last five quarters.
Revenue in the latest quarter increased by 10% compared to the average of the previous four quarters. Gross profit for the quarter rose by 26% over the average of the last four quarters. Net income saw a 9% increase compared to the average of the previous four quarters. The gross profit margin stood at 15.3%, improving from the 13.3% average of the previous four quarters. The tax rate for the quarter was 34.8%, lower than the 40.9% average over the past four quarters.
As of the week ending 28 February 2025, CPHL outperformed the KSE100 index by 90% over the past three months. Over the past year, CPHL outperformed the KSE100 index by 217%.
Indices Weighting:
CPHL has no exposure in the KSE100, KSE30, or KMI30 indices.
https://dps.psx.com.pk/download/document/248907.pdf
